The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models

Non-small cell lung cancer (NSCLC) sensitive to first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) often acquires resistance through secondary EGFR mutations, including the T790M mutation, aberrant c-Met receptor activity, or both. We assessed the ability of t...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Am J Cancer Res
Asıl Yazarlar: Friese-Hamim, Manja, Bladt, Friedhelm, Locatelli, Giuseppe, Stammberger, Uz, Blaukat, Andree
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: e-Century Publishing Corporation 2017
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5411803/
https://ncbi.nlm.nih.gov/pubmed/28469968
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller